EAMS scientific opinion: Avelumab in the treatment of bladder cancer
Study results show significant 7.1-month improvement in median overall survival with avelumab as first-line maintenance plus best supportive care (BSC) compared with BSC alone.
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via